{"id":"HAS_BLED_score.v0.0.2","gdl_version":"2.0","concept":"gt0001","language":{"original_language":"ISO_639-1::en"},"description":{"original_author":{"name":"Kevin Arjona","email":"kevin.arjona@cambio.se","organisation":"Cambio CDS","date":"2025-01-02"},"lifecycle_state":"Author draft","details":{"en":{"id":"en","purpose":"The HAS-BLED score is used to assess the risk of major bleeding in patients with atrial fibrillation (AF) undergoing anticoagulation therapy.","use":"Applicable for patients aged 18 and older with atrial fibrillation being evaluated for anticoagulation therapy. Ensure all input fields are filled in to calculate the total score accurately. The score ranges from 0 to 9, with higher scores indicating increased bleeding risk.","misuse":" This guideline is not applicable to patients with conditions other than AF, pediatric patients, or those not being considered for anticoagulation therapy. It should not replace clinical judgment.","copyright":"Â© Cambio CDS","keywords":["HAS-BLED","atrial fibrillation","anticoagulation","bleeding"]}},"other_details":{"references":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100. doi:10.1378/chest.10-0134\n\nLip GY, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121-1201. doi:10.1016/j.chest.2018.07.040\n\nKirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi:10.1093/eurheartj/ehw210\n\nJanuary CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol. 2014;64(21):2246-2280. doi:10.1016/j.jacc.2014.03.021\n\nKirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, et al. Management of atrial fibrillation patients presenting with ACS and/or undergoing PCI: a summary of the 2018 joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(7):3179-3184. doi:10.1093/eurheartj/ehy267","en":" The HAS-BLED score is used to assess the risk of major bleeding in patients with atrial fibrillation (AF) undergoing anticoagulation therapy."},"other_contributors":[]},"definition":{"data_bindings":{"gt0003":{"id":"gt0003","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.has_bled.v0","template_id":"openEHR-EHR-OBSERVATION.has_bled.v0","elements":{"gt0004":{"id":"gt0004","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0004]"},"gt0005":{"id":"gt0005","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0005]"},"gt0006":{"id":"gt0006","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0006]"},"gt0007":{"id":"gt0007","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0007]"},"gt0008":{"id":"gt0008","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0008]"},"gt0009":{"id":"gt0009","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0009]"},"gt0010":{"id":"gt0010","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0010]"},"gt0011":{"id":"gt0011","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0011]"},"gt0012":{"id":"gt0012","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0012]"}}},"gt0013":{"id":"gt0013","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.has_bled.v0","template_id":"openEHR-EHR-OBSERVATION.has_bled.v0","elements":{"gt0014":{"id":"gt0014","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0013]"}}},"gt0015":{"id":"gt0015","type":"OUTPUT","model_id":"openEHR-EHR-EVALUATION.health_risk.v1","template_id":"openEHR-EHR-EVALUATION.health_risk.v1","elements":{"gt0017":{"id":"gt0017","path":"/data[at0001]/items[at0016]/items[at0014]"},"gt0026":{"id":"gt0026","path":"/data[at0001]/items[at0016]/items[at0013]"}}}},"templates":{},"rules":{"gt0002":{"id":"gt0002","priority":8,"then":["$gt0014|Total score| = $gt0004|Hypertension|.value + $gt0005|Abnormal renal function|.value + $gt0006|Abnormal liver function|.value + $gt0007|Stroke|.value + $gt0008|Bleeding history or predisposition|.value + $gt0009|Labile INR|.value + $gt0010|Elderly|.value + $gt0011|Drugs concomitantly|.value + $gt0012|Alcohol concomitantly|.value"],"when":["$gt0004|Hypertension| != null && $gt0005|Abnormal renal function| != null && $gt0006|Abnormal liver function| != null && $gt0007|Stroke| != null && $gt0008|Bleeding history or predisposition| != null && $gt0009|Labile INR| != null && $gt0010|Elderly| != null && $gt0011|Drugs concomitantly| != null && $gt0012|Alcohol concomitantly|!=null"]},"gt0025":{"id":"gt0025","priority":7,"then":["$gt0026|Risk factor| = $gt0027|Patient has a relatively low risk for major bleeding: Anticoagulation should be considered.|.term","$gt0017|Description| ='Risk was 0.9% in one validation study (Lip 2011) and 1.13 bleeds per 100 patient-years in another validation study (Pisters 2010).'"],"when":["$gt0014|Total score| == 0"]},"gt0024":{"id":"gt0024","priority":6,"then":["$gt0026|Risk factor| = 'Patient has a relatively low risk for major bleeding: Anticoagulation should be considered'","$gt0017|Description| ='Risk was 3.4% in one validation study (Lip 2011) and 1.02 bleeds per 100 patient-years in another validation study (Pisters 2010).'"],"when":["$gt0014|Total score| == 1"]},"gt0023":{"id":"gt0023","priority":5,"then":["$gt0026|Risk factor| ='Anticoagulation can be considered, however patient does have moderate risk for major bleeding.'","$gt0017|Description| ='Risk was 4.1% in one validation study (Lip 2011) and 1.88 bleeds per 100 patient-years in another validation study (Pisters 2010).'"],"when":["$gt0014|Total score| == 2"]},"gt0022":{"id":"gt0022","priority":4,"then":["$gt0026|Risk factor| ='Patient is at high risk for major bleeding: Alternatives to anticoagulation should be considered'","$gt0017|Description| ='Risk was 5.8% in one validation study (Lip 2011) and 3.72 bleeds per 100 patient-years in another validation study (Pisters 2010).'"],"when":["$gt0014|Total score| == 3"]},"gt0021":{"id":"gt0021","priority":3,"then":["$gt0026|Risk factor| ='Patient is at high risk for major bleeding: Alternatives to anticoagulation should be considered'","$gt0017|Description| ='Risk was 8.9% in one validation study (Lip 2011) and 8.70 bleeds per 100 patient-years in another validation study (Pisters 2010).'"],"when":["$gt0014|Total score| == 4"]},"gt0020":{"id":"gt0020","priority":2,"then":["$gt0026|Risk factor| ='Patient is at high risk for major bleeding: Alternatives to anticoagulation should be considered'","$gt0017|Description| ='Risk was 9.1% in one validation study (Lip 2011) and 12.50 bleeds per 100 patient-years in another validation study (Pisters 2010).'"],"when":["$gt0014|Total score| == 5"]},"gt0019":{"id":"gt0019","priority":1,"then":["$gt0026|Risk factor| ='Patient is at high risk for major bleeding: Alternatives to anticoagulation should be considered'","$gt0017|Description| ='Scores greater than 5 were too rare to determine risk, but are likely over 10%.'"],"when":["$gt0014|Total score|  >5"]}}},"ontology":{"term_definitions":{"en":{"id":"en","terms":{"gt0001":{"id":"gt0001","description":"The HAS-BLED score is used to assess the risk of major bleeding in patients with atrial fibrillation (AF) undergoing anticoagulation therapy.","text":"HAS-BLED score"},"gt0002":{"id":"gt0002","text":"Total score","description":""},"gt0003":{"id":"gt0003","text":"openEHR-EHR-OBSERVATION.has_bled.v0"},"gt0004":{"id":"gt0004","text":"Hypertension"},"gt0005":{"id":"gt0005","text":"Abnormal renal function"},"gt0006":{"id":"gt0006","text":"Abnormal liver function"},"gt0007":{"id":"gt0007","text":"Stroke"},"gt0008":{"id":"gt0008","text":"Bleeding history or predisposition"},"gt0009":{"id":"gt0009","text":"Labile INR"},"gt0010":{"id":"gt0010","text":"Elderly"},"gt0011":{"id":"gt0011","text":"Drugs concomitantly"},"gt0012":{"id":"gt0012","text":"Alcohol concomitantly"},"gt0013":{"id":"gt0013","text":"openEHR-EHR-OBSERVATION.has_bled.v0"},"gt0014":{"id":"gt0014","text":"Total score"},"gt0015":{"id":"gt0015","text":"openEHR-EHR-EVALUATION.health_risk.v1"},"gt0017":{"id":"gt0017","text":"Description"},"gt0019":{"id":"gt0019","text":"Score > 5","description":""},"gt0020":{"id":"gt0020","text":"Score 5","description":""},"gt0021":{"id":"gt0021","text":"Score 4","description":""},"gt0022":{"id":"gt0022","text":"Score 3","description":""},"gt0023":{"id":"gt0023","text":"Score 2","description":""},"gt0024":{"id":"gt0024","text":"Score 1","description":""},"gt0025":{"id":"gt0025","text":"Score 0","description":""},"gt0026":{"id":"gt0026","text":"Risk factor"},"gt0027":{"text":"Patient has a relatively low risk for major bleeding: Anticoagulation should be considered.","id":"gt0027"}}}},"term_bindings":{}}}